Identification

Name
Procaine
Accession Number
DB00721  (APRD00650, DB05342)
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [2].

Structure
Thumb
Synonyms
  • 2-Diethylaminoethyl p-aminobenzoate
  • 4-aminobenzoic acid 2-diethylaminoethyl ester
  • Novocaine
  • p-Aminobenzoic acid 2-diethylaminoethyl ester
  • Procaina
  • Procainum
  • Vitamin H3
  • β-(diethylamino)ethyl 4-aminobenzoate
  • β-(diethylamino)ethyl p-aminobenzoate
Product Ingredients
IngredientUNIICASInChI Key
Procaine hydrochloride95URV01IDQ51-05-8HCBIBCJNVBAKAB-UHFFFAOYSA-N
Procaine nitrateT824SI1PU16192-92-3XUXYDJABBYUMRY-UHFFFAOYSA-N
Procaine phosphateA18LHT9ZXJ54812-66-7NPBISBZNYVWJOL-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novocain 20 mg/mlSolution2 %InfiltrationHospira, Inc.2001-06-012012-08-03Canada
Novocain Liq 2%Liquid2 %InfiltrationSanofi1920-12-312001-08-10Canada
International/Other Brands
Novocain
Categories
UNII
4Z8Y51M438
CAS number
59-46-1
Weight
Average: 236.3101
Monoisotopic: 236.152477894
Chemical Formula
C13H20N2O2
InChI Key
MFDFERRIHVXMIY-UHFFFAOYSA-N
InChI
InChI=1S/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3
IUPAC Name
2-(diethylamino)ethyl 4-aminobenzoate
SMILES
CCN(CC)CCOC(=O)C1=CC=C(N)C=C1

Pharmacology

Indication

Used as a local anesthetic primarily in oral surgery

Pharmacodynamics

Procaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Procaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Procaine is an ester anesthetic. It is metabolized in the plasma by the enzyme pseudocholinesterase through hydrolysis into para-aminobenzoic acid (PABA), which is then excreted by the kidneys into the urine.

Mechanism of action

Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.

TargetActionsOrganism
ASodium channel protein type 10 subunit alpha
inhibitor
Human
AGlutamate receptor ionotropic, NMDA 3A
antagonist
Human
A5-hydroxytryptamine receptor 3A
antagonist
Human
ASodium-dependent dopamine transporter
inhibitor
Human
UNeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
UDNA
binder
Human
UCalcium-activated potassium channel
binder
Human
UPhospholipase A2
inhibitor
Human
ULysophospholipase
inhibitor
Human
UMonoamine oxidase
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hydrolysis by plasma esterases to PABA

Route of elimination

With normal kidney function, the drug is excreted rapidly by tubular excretion.

Half life

7.7 minutes

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Procaine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Procaine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Procaine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Procaine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Procaine.Experimental, Illicit
4-MethoxyamphetamineProcaine may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Procaine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Procaine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Procaine.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Procaine is combined with Abediterol.Investigational
AcarboseProcaine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololProcaine may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Procaine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Procaine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Procaine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Procaine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Procaine.Experimental
AlbiglutideProcaine may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Procaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Procaine.Approved, Illicit
AliskirenProcaine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Procaine is combined with Allopregnanolone.Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Procaine.Approved, Investigational
AlogliptinProcaine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Procaine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Procaine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Procaine.Approved, Illicit, Investigational
AlprenololProcaine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Procaine.Approved
AmbrisentanProcaine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineProcaine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Procaine is combined with Amisulpride.Approved, Investigational
AmitriptylineProcaine may increase the serotonergic activities of Amitriptyline.Approved
AmitriptylinoxideProcaine may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmlodipineProcaine may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Procaine.Approved, Illicit
AmoxapineProcaine may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Procaine is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Procaine.Approved, Illicit, Investigational
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Procaine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Procaine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Procaine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Procaine is combined with Arformoterol.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Procaine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Procaine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Procaine.Approved
AtenololProcaine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineProcaine may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineProcaine may increase the hypertensive activities of Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Procaine is combined with Azaperone.Investigational, Vet Approved
AzelastineProcaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Procaine.Approved
BambuterolThe risk or severity of adverse effects can be increased when Procaine is combined with Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Procaine is combined with Barbital.Illicit
BenazeprilProcaine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideProcaine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Procaine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Procaine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Procaine is combined with Benzocaine.Approved, Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Procaine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Procaine is combined with Benzyl alcohol.Approved
BepridilProcaine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Procaine.Approved, Investigational
BetaxololProcaine may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineProcaine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Procaine is combined with Bezafibrate.Approved, Investigational
BietaserpineProcaine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostProcaine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololProcaine may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Procaine is combined with Bitolterol.Withdrawn
BosentanProcaine may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Procaine may increase the hypotensive activities of BQ-123.Investigational
BretyliumProcaine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe metabolism of Brexpiprazole can be decreased when combined with Procaine.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved
BrofaromineBrofaromine may increase the hypertensive activities of Procaine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Procaine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Procaine is combined with Bromisoval.Experimental
BromocriptineProcaine may increase the hypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Procaine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Procaine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Procaine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Procaine.Approved, Investigational
BupranololProcaine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Procaine.Approved, Illicit, Investigational, Vet Approved
BuprenorphineProcaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Procaine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Procaine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Procaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Procaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Procaine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Procaine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Procaine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Procaine.Approved, Illicit, Vet Approved
ButriptylineProcaine may increase the serotonergic activities of Butriptyline.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Procaine.Approved
CadralazineProcaine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineProcaine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinProcaine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanProcaine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilProcaine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilProcaine may increase the hypotensive activities of Candoxatril.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Procaine is combined with Canertinib.Investigational
CaptoprilProcaine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Procaine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Procaine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Procaine.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Procaine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Procaine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Procaine.Withdrawn
CarteololProcaine may increase the hypotensive activities of Carteolol.Approved
CarvedilolProcaine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololProcaine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Procaine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Procaine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Procaine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Procaine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Procaine is combined with Chloroprocaine.Approved
ChlorothiazideProcaine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Procaine.Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Procaine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Procaine.Approved, Investigational, Vet Approved
ChlorpropamideProcaine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Procaine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe therapeutic efficacy of Procaine can be decreased when used in combination with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorthalidoneProcaine may increase the hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Procaine.Approved
CicletanineProcaine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilProcaine may increase the hypotensive activities of Cilazapril.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Procaine.Approved, Vet Approved
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Procaine.Approved, Investigational
CirazolineProcaine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Procaine.Approved
ClemastineProcaine may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Procaine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Procaine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Procaine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Procaine is combined with clomethiazole.Investigational
ClomipramineProcaine may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe therapeutic efficacy of Procaine can be decreased when used in combination with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Procaine.Approved, Illicit
ClonidineProcaine may increase the hypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Procaine is combined with Clopenthixol.Experimental
CloranololProcaine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Procaine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Procaine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Procaine.Approved
CocaineThe risk or severity of adverse effects can be increased when Procaine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Procaine.Approved, Illicit
CryptenamineProcaine may increase the hypotensive activities of Cryptenamine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Procaine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Procaine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Procaine.Approved
CyclopenthiazideProcaine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Procaine is combined with Cyclopropane.Experimental
CyclothiazideProcaine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineProcaine may increase the anticholinergic activities of Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Procaine.Approved, Investigational
DapagliflozinProcaine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Procaine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Procaine.Investigational
DebrisoquinProcaine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilProcaine may increase the hypotensive activities of Delapril.Experimental
DemeclocyclineThe therapeutic efficacy of Procaine can be decreased when used in combination with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Procaine is combined with Deramciclane.Investigational
DeserpidineProcaine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Procaine.Approved
DesipramineProcaine may increase the serotonergic activities of Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Procaine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Procaine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Procaine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Procaine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Procaine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Procaine.Approved, Vet Approved
DexmethylphenidateProcaine may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Procaine.Approved, Illicit
DextromethorphanProcaine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Procaine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Procaine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Procaine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Procaine.Approved, Illicit, Investigational, Vet Approved
DiazoxideProcaine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinProcaine may increase the serotonergic activities of Dibenzepin.Experimental
Diethyl etherThe risk or severity of adverse effects can be increased when Procaine is combined with Diethyl ether.Experimental
DiethylnorspermineProcaine may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionProcaine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Procaine.Approved, Illicit
DihydralazineProcaine may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Procaine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Procaine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Procaine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Procaine.Experimental, Illicit
DiltiazemProcaine may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Procaine.Approved
DimetacrineProcaine may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Procaine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Procaine.Approved, Illicit
DipivefrinProcaine may increase the hypertensive activities of Dipivefrin.Approved
DisopyramideProcaine may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Procaine is combined with Disulfiram.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Procaine is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Procaine is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Procaine is combined with Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Procaine is combined with Doramectin.Vet Approved
DorzolamideProcaine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinProcaine may increase the serotonergic activities of Dosulepin.Approved
DoxapramProcaine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinProcaine may increase the hypotensive activities of Doxazosin.Approved
DoxepinProcaine may increase the serotonergic activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Procaine is combined with Doxofylline.Approved, Investigational
DoxycyclineThe therapeutic efficacy of Procaine can be decreased when used in combination with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Procaine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Procaine.Experimental, Illicit
DroxidopaProcaine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideProcaine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Procaine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Procaine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Procaine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Procaine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Procaine.Approved, Investigational
EfonidipineProcaine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Procaine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Procaine is combined with Eltanolone.Investigational
EmpagliflozinProcaine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilProcaine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatProcaine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineProcaine may increase the hypotensive activities of Endralazine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Procaine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Procaine.Approved, Investigational
EpanololProcaine may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Procaine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpoprostenolProcaine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanProcaine may increase the hypotensive activities of Eprosartan.Approved
ErgonovineProcaine may increase the hypertensive activities of Ergonovine.Approved
ErgotamineProcaine may increase the hypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Procaine.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Procaine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Procaine.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Procaine is combined with Etafedrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Procaine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Procaine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Procaine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Procaine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Procaine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Procaine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Procaine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Procaine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Procaine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Procaine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Procaine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Procaine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Procaine.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Procaine.Illicit, Vet Approved
ExenatideProcaine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Procaine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Procaine.Approved
FelodipineProcaine may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Procaine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineProcaine may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamProcaine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Procaine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Procaine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidProcaine may increase the hypotensive activities of Ferulic acid.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Procaine.Approved, Investigational
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Procaine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Procaine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Procaine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Procaine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Procaine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Procaine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Procaine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Procaine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Procaine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Procaine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Procaine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Procaine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Procaine is combined with Formoterol.Approved, Investigational
FosinoprilProcaine may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Procaine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Procaine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Procaine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Procaine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Procaine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Procaine.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Procaine.Approved, Illicit, Investigational
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Procaine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Procaine is combined with Gepirone.Investigational
GliclazideProcaine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideProcaine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideProcaine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Procaine is combined with Glutethimide.Approved, Illicit
GlyburideProcaine may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzProcaine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelProcaine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineProcaine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineProcaine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Procaine.Approved, Investigational
GuanoclorProcaine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzProcaine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanProcaine may increase the hypotensive activities of Guanoxan.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Procaine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Procaine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Procaine is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the hypertensive activities of Procaine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Procaine.Approved, Illicit, Investigational
HexamethoniumProcaine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Procaine is combined with Hexobarbital.Approved
HexoprenalineThe risk or severity of adverse effects can be increased when Procaine is combined with Hexoprenaline.Approved, Withdrawn
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Procaine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Procaine.Experimental
HydralazineProcaine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideProcaine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Procaine is combined with Hydrocodone.Approved, Illicit
HydrocodoneProcaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideProcaine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Procaine.Approved, Illicit
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Procaine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Procaine.Approved
ImidaprilProcaine may increase the hypotensive activities of Imidapril.Investigational
ImipramineProcaine may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Procaine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Procaine.Investigational, Withdrawn
IndapamideProcaine may increase the hypotensive activities of Indapamide.Approved
IndenololProcaine may increase the hypotensive activities of Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Procaine is combined with Indiplon.Investigational
IndoraminProcaine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartProcaine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirProcaine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineProcaine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineProcaine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanProcaine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproProcaine may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Procaine.Approved
IprindoleProcaine may increase the serotonergic activities of Iprindole.Experimental
IproclozideIproclozide may increase the hypertensive activities of Procaine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Procaine.Withdrawn
IrbesartanProcaine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Procaine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Procaine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Procaine.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Procaine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Procaine is combined with Isoprenaline.Approved, Investigational
IsradipineProcaine may increase the hypotensive activities of Isradipine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Procaine.Approved, Vet Approved
KetanserinProcaine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Procaine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Procaine.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Procaine.Approved, Nutraceutical, Withdrawn
LabetalolProcaine may increase the hypotensive activities of Labetalol.Approved
LacidipineProcaine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Procaine.Approved, Investigational
LatanoprostProcaine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineProcaine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Procaine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Procaine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Procaine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Procaine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Procaine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Procaine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Procaine.Approved, Investigational
LevonordefrinProcaine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Procaine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Procaine is combined with Levosalbutamol.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Procaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Procaine is combined with Linezolid.Approved, Investigational
LinsidomineProcaine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideProcaine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Procaine.Approved, Investigational
LisinoprilProcaine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Procaine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Procaine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Procaine.Illicit
LofepramineProcaine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Procaine can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Procaine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Procaine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Procaine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Procaine is combined with Lormetazepam.Approved
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Procaine.Approved
LosartanProcaine may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Procaine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Procaine.Approved, Investigational
LymecyclineThe therapeutic efficacy of Procaine can be decreased when used in combination with Lymecycline.Approved, Investigational
MacitentanProcaine may increase the hypotensive activities of Macitentan.Approved
Magnesium sulfateThe therapeutic efficacy of Procaine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineProcaine may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Procaine is combined with Maprotiline.Approved, Investigational
MebanazineMebanazine may increase the hypertensive activities of Procaine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Procaine is combined with Mebicar.Experimental
MecamylamineProcaine may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminProcaine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Procaine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Procaine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Procaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Procaine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenProcaine may increase the serotonergic activities of Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Procaine is combined with Melperone.Approved, Investigational
MemantineThe risk or severity of adverse effects can be increased when Procaine is combined with Memantine.Approved, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Procaine.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Procaine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Procaine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Procaine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Procaine.Experimental
MequitazineProcaine may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Procaine is combined with Mesoridazine.Approved, Investigational
MetaraminolProcaine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Procaine.Approved
MetforminProcaine may increase the hypoglycemic activities of Metformin.Approved
MethacyclineThe therapeutic efficacy of Procaine can be decreased when used in combination with Methacycline.Approved, Investigational
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Procaine.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Procaine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Procaine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Procaine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Procaine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Procaine.Approved
MethoserpidineProcaine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineProcaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineProcaine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Procaine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Procaine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Procaine.Approved
MethyldopaThe risk or severity of hypertension can be increased when Procaine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Procaine.Experimental
Methylene blueProcaine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateProcaine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Procaine is combined with Methylphenobarbital.Approved
MethysergideThe metabolism of Methysergide can be decreased when combined with Procaine.Approved
MetipranololProcaine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneProcaine may increase the hypotensive activities of Metolazone.Approved
MetoprololProcaine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineProcaine may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Procaine is combined with Mianserin.Approved, Investigational
MibefradilProcaine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Procaine.Approved, Illicit
MidodrineProcaine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Procaine.Experimental, Illicit, Investigational
MifepristoneProcaine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolProcaine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Procaine.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Procaine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational
MinoxidilProcaine may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Procaine is combined with Mirtazapine.Approved
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Procaine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Procaine is combined with Moclobemide.Approved, Investigational
MoexiprilProcaine may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Procaine is combined with Molindone.Approved
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Procaine.Approved, Investigational
MoxonidineProcaine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineProcaine may increase the hypotensive activities of Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational
NadololProcaine may increase the hypotensive activities of Nadolol.Approved
NaftopidilProcaine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Procaine.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Procaine.Investigational
NaphazolineProcaine may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Procaine.Approved, Investigational
NateglinideProcaine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololProcaine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Procaine.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Procaine.Withdrawn
NicardipineProcaine may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilProcaine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineProcaine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineProcaine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineProcaine may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineProcaine may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Procaine.Approved
NitrendipineProcaine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideProcaine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Procaine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Procaine is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Procaine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Procaine.Approved, Illicit
NortriptylineProcaine may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Procaine.Withdrawn
OlanzapineProcaine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlmesartanProcaine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Procaine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Procaine.Approved
OmapatrilatProcaine may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Procaine is combined with Ondansetron.Approved
OpipramolProcaine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Procaine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Procaine is combined with Orciprenaline.Approved
OrphenadrineProcaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Procaine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Procaine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Procaine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Procaine is combined with Oxybuprocaine.Approved, Investigational
OxymetazolineProcaine may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxytetracyclineThe therapeutic efficacy of Procaine can be decreased when used in combination with Oxytetracycline.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Procaine.Approved
ParaldehydeProcaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the hypertensive activities of Procaine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Procaine.Approved, Investigational
PenbutololProcaine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Procaine is combined with Penfluridol.Experimental
PenimepicyclineThe therapeutic efficacy of Procaine can be decreased when used in combination with Penimepicycline.Experimental
PentamidineProcaine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Procaine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Procaine.Approved, Investigational, Vet Approved
PentoliniumProcaine may increase the hypotensive activities of Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Procaine is combined with Perazine.Approved, Investigational
PergolideProcaine may increase the hypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilProcaine may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Procaine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Procaine.Approved
PethidineProcaine may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Procaine is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Procaine.Experimental
PhendimetrazineProcaine may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Procaine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Procaine is combined with Phenibut.Experimental
PheniprazinePheniprazine may increase the hypertensive activities of Procaine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Procaine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Procaine.Experimental
PhenoxybenzamineProcaine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Procaine is combined with Phenoxyethanol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Procaine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Procaine.Approved, Illicit
PhentolamineProcaine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineProcaine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Procaine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Procaine.Approved, Vet Approved
PholcodinePholcodine may increase the serotonergic activities of Procaine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Procaine.Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Procaine.Approved
PinacidilProcaine may increase the hypotensive activities of Pinacidil.Approved
PindololProcaine may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneProcaine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Procaine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Procaine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Procaine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Procaine.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Procaine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Procaine.Withdrawn
PizotifenProcaine may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorProcaine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideProcaine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Procaine.Approved
PramipexoleProcaine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideProcaine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Procaine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Procaine is combined with Prazepam.Approved, Illicit
PrazosinProcaine may increase the hypotensive activities of Prazosin.Approved
PregabalinThe therapeutic efficacy of Procaine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Procaine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Procaine.Approved, Vet Approved
ProcarbazineProcaine may increase the hypertensive activities of Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Procaine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Procaine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Procaine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Procaine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Procaine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Procaine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Procaine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Procaine is combined with Propoxycaine.Approved
PropranololProcaine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Procaine is combined with Protokylol.Approved, Vet Approved
ProtriptylineProcaine may increase the serotonergic activities of Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Procaine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Procaine is combined with PSD502.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Procaine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Procaine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Procaine.Approved
QuinaprilProcaine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineProcaine may increase the hypoglycemic activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Procaine is combined with Quinisocaine.Experimental
RacepinephrineProcaine may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Procaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Procaine.Approved, Investigational
RamiprilProcaine may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Procaine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Procaine.Approved
RemikirenProcaine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Procaine.Approved, Withdrawn
RepaglinideProcaine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineProcaine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Procaine is combined with Reserpine.Approved, Investigational
RilmenidineProcaine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatProcaine may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Procaine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Procaine is combined with Ritanserin.Investigational
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Procaine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Procaine is combined with Ritodrine.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Procaine.Approved
RolitetracyclineThe therapeutic efficacy of Procaine can be decreased when used in combination with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Procaine is combined with Romifidine.Vet Approved
RopiniroleProcaine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Procaine.Approved
RosiglitazoneProcaine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineProcaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Procaine.Approved
SafrazineSafrazine may increase the hypertensive activities of Procaine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Procaine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Procaine is combined with Salmeterol.Approved
SaprisartanProcaine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinProcaine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Procaine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Procaine.Approved, Vet Approved
SelegilineSelegiline may increase the hypertensive activities of Procaine.Approved, Investigational, Vet Approved
SelexipagProcaine may increase the hypotensive activities of Selexipag.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Procaine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Procaine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Procaine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Procaine.Approved, Vet Approved
SitagliptinProcaine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanProcaine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved
SpiraprilProcaine may increase the hypotensive activities of Spirapril.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Procaine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Procaine.Approved, Investigational
SulfadiazineProcaine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleProcaine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleProcaine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Procaine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Procaine is combined with Sultopride.Experimental
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Procaine.Approved, Investigational
SunitinibProcaine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantProcaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalinololProcaine may increase the hypotensive activities of Talinolol.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Procaine is combined with Tandospirone.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Procaine.Approved
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Procaine.Approved, Investigational
Technetium Tc-99m tilmanoceptProcaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved, Investigational
TelmisartanProcaine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Procaine.Approved, Investigational
TemocaprilProcaine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Procaine is combined with Terbutaline.Approved
TerlipressinProcaine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Procaine is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe therapeutic efficacy of Procaine can be decreased when used in combination with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Procaine.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Procaine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Procaine is combined with Tetrodotoxin.Investigational
TetryzolineProcaine may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideProcaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineProcaine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Procaine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Procaine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Procaine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Procaine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Procaine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Procaine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Procaine is combined with Tiapride.Approved, Investigational
TiboloneProcaine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenProcaine may increase the hypotensive activities of Ticrynafen.Withdrawn
TigecyclineThe therapeutic efficacy of Procaine can be decreased when used in combination with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Procaine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Procaine.Experimental
TimololProcaine may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Procaine.Approved, Investigational
TolazamideProcaine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineProcaine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideProcaine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Procaine.Approved, Withdrawn
TolonidineProcaine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Procaine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Procaine.Approved
TorasemideProcaine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Procaine.Approved, Investigational
TrandolaprilProcaine may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypertensive activities of Procaine.Approved, Investigational
TravoprostProcaine may increase the hypotensive activities of Travoprost.Approved
TrazodoneProcaine may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilProcaine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Procaine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Procaine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideProcaine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Procaine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Procaine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Procaine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Procaine.Approved, Vet Approved
TrimazosinProcaine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanProcaine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineProcaine may increase the serotonergic activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Procaine.Approved
UnoprostoneProcaine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilProcaine may increase the hypotensive activities of Urapidil.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Procaine.Approved, Investigational
ValsartanProcaine may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Procaine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Procaine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Procaine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Procaine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Procaine.Approved
VincamineProcaine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineProcaine may increase the hypotensive activities of Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Procaine is combined with Vinyl ether.Experimental
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Procaine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Procaine is combined with Xenon.Experimental
XipamideProcaine may increase the hypotensive activities of Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Procaine is combined with Xylazine.Vet Approved
XylometazolineProcaine may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Procaine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Procaine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Procaine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Procaine.Approved
ZofenoprilProcaine may increase the hypotensive activities of Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Procaine is combined with Zolazepam.Vet Approved
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Procaine.Approved, Investigational
ZolpidemProcaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Procaine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Procaine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Procaine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Procaine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US812554
General References
  1. Gentry CL, Lukas RJ: Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes. J Pharmacol Exp Ther. 2001 Dec;299(3):1038-48. [PubMed:11714893]
  2. Clinical Trial NCT00299897 [Link]
External Links
Human Metabolome Database
HMDB0014859
KEGG Drug
D08422
KEGG Compound
C07375
PubChem Compound
4914
PubChem Substance
46507724
ChemSpider
4745
BindingDB
64452
ChEBI
8430
ChEMBL
CHEMBL569
Therapeutic Targets Database
DAP000296
PharmGKB
PA451110
IUPHAR
4291
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Procaine
ATC Codes
S01HA05 — ProcaineN01BA52 — Procaine, combinationsN01BA02 — ProcaineC05AD05 — Procaine
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Not Yet RecruitingTreatmentNasopharyngeal Neoplasms / Vesicular Stomatitis1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableRecruitingPreventionArterial Hypotension1

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
  • Consolidated pharmaceutical group inc
  • King pharmaceuticals inc
  • Parke davis div warner lambert co
  • Pfizer laboratories div pfizer inc
  • Hospira inc
  • Abraxis pharmaceutical products
  • Bel mar laboratories inc
  • Elkins sinn div ah robins co inc
  • Gd searle llc
  • Miles laboratories inc
  • Watson laboratories inc
Packagers
  • APP Pharmaceuticals
  • Hospira Inc.
  • King Pharmaceuticals Inc.
  • Merit Pharmaceuticals
  • Monarch Pharmacy
  • Physicians Total Care Inc.
  • Prescript Pharmaceuticals
  • Smiths Medical ASD Inc.
  • Spectrum Pharmaceuticals
  • Torrance Co.
Dosage forms
FormRouteStrength
SolutionInfiltration2 %
LiquidInfiltration2 %
Prices
Unit descriptionCostUnit
Novocain 10% ampul2.4USD ml
Novocain 1% ampul1.79USD ml
Procaine hcl crystals1.76USD g
Nesacaine-mpf 3% vial1.34USD ml
Nesacaine-mpf 2% vial1.28USD ml
Nesacaine 2% vial0.74USD ml
Nesacaine 1% vial0.72USD ml
Chloroprocaine 3% vial0.33USD ml
Chloroprocaine 2% vial0.26USD ml
Procaine hcl 2% vial0.15USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)61 °CPhysProp
water solubility9450 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.14AVDEEF,A (1997)
logS-1.4ADME Research, USCD
pKa8.05 (at 15 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility6.81 mg/mLALOGPS
logP2.1ALOGPS
logP1.88ChemAxon
logS-1.5ALOGPS
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.56 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity70.3 m3·mol-1ChemAxon
Polarizability26.81 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9747
Blood Brain Barrier+0.9533
Caco-2 permeable+0.6291
P-glycoprotein substrateSubstrate0.587
P-glycoprotein inhibitor INon-inhibitor0.9492
P-glycoprotein inhibitor IINon-inhibitor0.9884
Renal organic cation transporterNon-inhibitor0.684
CYP450 2C9 substrateNon-substrate0.8646
CYP450 2D6 substrateNon-substrate0.6643
CYP450 3A4 substrateNon-substrate0.6456
CYP450 1A2 substrateNon-inhibitor0.6308
CYP450 2C9 inhibitorNon-inhibitor0.9312
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9294
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7918
Ames testNon AMES toxic0.6165
CarcinogenicityNon-carcinogens0.6462
BiodegradationNot ready biodegradable0.9449
Rat acute toxicity2.5160 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8728
hERG inhibition (predictor II)Non-inhibitor0.6234
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-000i-9200000000-44eb49be9b2baedfebdd
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-0090000000-7c7d7173da9393c2d059
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0910000000-279febfbe258e2ce2807
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0uk9-0900000000-997e743a0702a7a5b54f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-2900000000-39c6b968e8d17c932e10
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00dl-9700000000-157dc94224e66c932ae8
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0w29-0900000000-050d794abd6d3a7e685d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01w0-1940000000-d4d5195f000d2d633df7
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Aminobenzoic acids and derivatives / Benzoyl derivatives / Aniline and substituted anilines / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Primary amines / Organopnictogen compounds / Organooxygen compounds
show 2 more
Substituents
Aminobenzoic acid or derivatives / Benzoate ester / Benzoyl / Aniline or substituted anilines / Amino acid or derivatives / Tertiary aliphatic amine / Tertiary amine / Carboxylic acid ester / Carboxylic acid derivative / Monocarboxylic acid or derivatives
show 10 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, substituted aniline, benzoate ester (CHEBI:8430)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
Gene Name
SCN10A
Uniprot ID
Q9Y5Y9
Uniprot Name
Sodium channel protein type 10 subunit alpha
Molecular Weight
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Brau ME, Vogel W, Hempelmann G: Fundamental properties of local anesthetics: half-maximal blocking concentrations for tonic block of Na+ and K+ channels in peripheral nerve. Anesth Analg. 1998 Oct;87(4):885-9. [PubMed:9768788]
  4. Katalymov LL: [The effect of inhibitors of sodium permeability (novocaine and tetrodotoxin) on the trace depolarization of myelinated nerve fibers]. Fiziol Zh Im I M Sechenova. 1995 Sep;81(9):127-33. [PubMed:8581044]
  5. Creveling CR, Bell ME, Burke TR Jr, Chang E, Lewandowski-Lovenberg GA, Kim CH, Rice KC, Daly JW: Procaine isothiocyanate: an irreversible inhibitor of the specific binding of [3H]batrachotoxinin-A benzoate to sodium channels. Neurochem Res. 1990 Apr;15(4):441-8. [PubMed:2167458]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein phosphatase 2a binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May ...
Gene Name
GRIN3A
Uniprot ID
Q8TCU5
Uniprot Name
Glutamate receptor ionotropic, NMDA 3A
Molecular Weight
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hahnenkamp K, Durieux ME, Hahnenkamp A, Schauerte SK, Hoenemann CW, Vegh V, Theilmeier G, Hollmann MW: Local anaesthetics inhibit signalling of human NMDA receptors recombinantly expressed in Xenopus laevis oocytes: role of protein kinase C. Br J Anaesth. 2006 Jan;96(1):77-87. Epub 2005 Nov 18. [PubMed:16299047]
  4. Nishizawa N, Shirasaki T, Nakao S, Matsuda H, Shingu K: The inhibition of the N-methyl-D-aspartate receptor channel by local anesthetics in mouse CA1 pyramidal neurons. Anesth Analg. 2002 Feb;94(2):325-30, table of contents. [PubMed:11812692]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Fan P, Weight FF: Procaine impairs the function of 5-HT3 receptor-ion channel complex in rat sensory ganglion neurons. Neuropharmacology. 1994 Dec;33(12):1573-9. [PubMed:7539114]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Sato T, Kitayama S, Mitsuhata C, Ikeda T, Morita K, Dohi T: Selective inhibition of monoamine neurotransmitter transporters by synthetic local anesthetics. Naunyn Schmiedebergs Arch Pharmacol. 2000 Feb;361(2):214-20. [PubMed:10685879]
  2. Wilcox KM, Kimmel HL, Lindsey KP, Votaw JR, Goodman MM, Howell LL: In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys. Synapse. 2005 Dec 15;58(4):220-8. [PubMed:16206183]
  3. Kiyatkin EA, Brown PL: The role of peripheral and central sodium channels in mediating brain temperature fluctuations induced by intravenous cocaine. Brain Res. 2006 Oct 30;1117(1):38-53. Epub 2006 Sep 7. [PubMed:16956595]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Wang H, Zhang Y, Li ST: The effect of local anesthetics on the inhibition of adult muscle-type nicotinic acetylcholine receptors by nondepolarizing muscle relaxants. Eur J Pharmacol. 2010 Mar 25;630(1-3):29-33. doi: 10.1016/j.ejphar.2009.12.028. Epub 2010 Jan 4. [PubMed:20045405]
6. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Villar-Garea A, Fraga MF, Espada J, Esteller M: Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003 Aug 15;63(16):4984-9. [PubMed:12941824]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Voltage-gated potassium channel activity
Specific Function
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activati...
Gene Name
KCNMA1
Uniprot ID
Q12791
Uniprot Name
Calcium-activated potassium channel subunit alpha-1
Molecular Weight
137558.115 Da
References
  1. Benham CD, Bolton TB, Lang RJ, Takewaki T: The mechanism of action of Ba2+ and TEA on single Ca2+-activated K+ -channels in arterial and intestinal smooth muscle cell membranes. Pflugers Arch. 1985 Feb;403(2):120-7. [PubMed:2580269]
8. Phospholipase A2
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
References
  1. Kunze H, Nahas N, Traynor JR, Wurl M: Effects of local anaesthetics on phospholipases. Biochim Biophys Acta. 1976 Jul 20;441(1):93-102. [PubMed:952985]
9. Lysophospholipase
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
References
  1. Kawashima Y, Nakagawa M, Suzuki Y, Uchiyama M: The relationship between chain elongation of palmitoyl-CoA and phospholipid content in rat liver microsomes. Biochim Biophys Acta. 1976 Aug 23;441(2):173-80. [PubMed:952986]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...

Components:
References
  1. MacFarlane MD: Procaine HCl (Gerovital H3): a weak, reversible, fully competitive inhibitor of monoamine oxidase. Fed Proc. 1975 Jan;34(1):108-10. [PubMed:1109354]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Perez-Guillermo F, Delgado EM, Vidal CJ: Inhibition of human serum and rabbit muscle cholinesterase by local anesthetics. Biochem Pharmacol. 1987 Nov 1;36(21):3593-6. [PubMed:3675616]
  2. Dorokhov KE, Grigorian GL: [Binding of reversible spin-labeled inhibitors with an butyrylcholinesterase active center]. Biofizika. 1986 Sep-Oct;31(5):746-51. [PubMed:3022829]

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 09:48